Potential benefits of expanded palivizumab in American Indian children under the age of 2-years.

Abstract

Respiratory syncytial virus (RSV) causes a severe respiratory syndrome that disparately impacts American Indian communities. We significantly reduced RSV-related infections and hospitalizations through the expanded the use of palivizumab, an approved yet commonly restricted prophylactic monoclonal therapy.